Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: Click here for what to expect at ChristianaCare during COVID-19

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: Click here for what to expect at ChristianaCare during COVID-19

Cancer Research

 

At ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

Dr. Bruce Boman conducts cancer research at ChristianaCare Dr. Pradhan-Bhatt leads cancer research at ChristianaCare Dr. Eric Kmiec conducts gene editing cancer research at ChristianaCare Dr. Mourtada conducts radiation oncology cancer research at ChristianaCare Dr. Sims-Mourtada irradiates a cancer research specimen at ChristianaCare

At ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, ground-breaking cancer research is every-day reality. The Graham Cancer Center brings scientists and clinicians together to investigate innovative ways to diagnose cancer earlier and treat it more effectively.

Because of its membership in the prestigious National Cancer Institute NCI Community Oncology Research Program (NCORP), the Graham Cancer Center offers leading-edge NCORP clinical trials to the patients we are privileged to serve. The Graham Cancer Center also offers a robust pharmaceutical clinical trials program.

In addition to clinical trials, the Graham Cancer Center has a translational cancer research program, the Cawley Center for Translational Cancer Research (CTCR) that brings scientific discoveries from the bench to the bedside of patients, investigating breast cancer, colon cancer, radiation oncology and tissue engineering. The Graham Cancer Center conducts industry-leading genetic engineering cancer research at the Gene Editing Institute.

The Graham Cancer Center collaborates with other institutions in cancer research, having close partnerships with The Wistar Institute, the University of Delaware, Nemours / A.I. du Pont Hospital for Children, Rice University / BioScience Research Collaborative and the Delaware Biotechnology Institute, among others.